Denmark Discontinues Deploying J&J - Janssen COVID-19 Vaccine
The Danish Health Authority announced today it concluded that the benefits of using the COVID-19 vaccine from Johnson & Johnson do not outweigh the risk of causing the possible adverse effect in those who receive the vaccine.
Therefore, as of May 3, 2021, the Danish Health Authority will continue the Danish mass COVID-19 vaccination program without the COVID-19 vaccine from Johnson & Johnson (Janssen).
'In the midst of an epidemic, this has been a difficult decision to make, especially since we have also had to discontinue using the COVID-19 vaccine from AstraZeneca.' commented Deputy Director-General Helene Probst.
'However, taking the present situation in Denmark into account, what we are currently losing in our effort to prevent severe illness from COVID-19 cannot outweigh the risk of causing possible side effects in the form of severe blood clots in those we vaccinate. One should also bear in mind that, going forward, we will first and foremost be vaccinating younger and healthy people,' stated Probst in a press release.
The Danish Health Authority will continue to review the ongoing release of data from the U.S. Health and Drug Administration that due to the current epidemic in the USA, has chosen to include the COVID-19 vaccine from Johnson & Johnson in their vaccination campaign.
The first approved vaccine against COVID-19 in Denmark is called Comirnaty and was developed by the German company BioNTech in collaboration with the American company Pfizer. The supplies of the mRNA Comirnaty vaccine received in Denmark are manufactured in Germany and Belgium.
The second vaccine approved for use in Denmark was developed by the American company Moderna. The mRNA COVID-19 Vaccine Moderna is manufactured in Switzerland and Spain.